Urotensin-II As a Promising Key-Point of Cardiovascular Disturbances Sequel

Ashot Avagimyan1, Albina Kajaia2, Luiza Gabunia2

  • 1Department of Pathological Anatomy and Clinical Morphology, Yerevan State Medical University after M. Heratsi, Republic of Armenia.

Insights

Uncontrolled arterial hypertension is a major medical challenge. This study proposes urotensin II as a novel therapeutic target for managing hypertension, reflecting international medical perspectives.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Arterial hypertension remains a critical global health issue with persistent challenges in blood pressure control.
  • The increasing prevalence of uncontrolled arterial hypertension necessitates novel therapeutic strategies.
  • Understanding the intricate mechanisms underlying hypertension development and progression is a key focus in cardiovascular research.

Purpose of the Study:

  • To introduce urotensin II as a potential new therapeutic target in the pathogenesis of arterial hypertension.
  • To present a unified concept from Armenian, Georgian, and Iranian medical schools regarding urotensin II's role in hypertension.
  • To explore the mechanisms by which urotensin II influences blood pressure regulation.

Main Methods:

  • Literature review and synthesis of existing research on urotensin II and arterial hypertension.
  • Multidisciplinary expert consensus building among international working groups.
  • Analysis of preclinical and clinical data related to urotensin II pathways.

Main Results:

  • Urotensin II is implicated as a significant factor in the development and progression of arterial hypertension.
  • Evidence suggests urotensin II plays a role in vascular tone regulation and endothelial function.
  • The study highlights potential for targeting urotensin II pathways for improved hypertension management.

Conclusions:

  • Urotensin II represents a promising novel therapeutic target for arterial hypertension.
  • Further research into urotensin II's role could lead to innovative treatment approaches.
  • This collaborative work integrates diverse medical insights into a cohesive understanding of urotensin II in hypertension.

Related Concept Videos

Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
148
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
97
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
1.1K
Hormonal Regulation of Blood Pressure01:17

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
3.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
561